Literature DB >> 3501387

Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis.

M Onji1, H Kondoh, N Horiike, S Yamaguchi, Y Ogawa, I Kumon, Y Ohta.   

Abstract

Eleven patients with hepatitis B (HB) virus related chronic hepatitis were treated with recombinant interleukin 2 (rIL 2). Two hundred and fifty to 1000 units were given intravenously once daily for seven to 28 days. In five patients serum glutamic pyruvic transaminase activity rose transiently. Six patients showed a decrease in HBV DNA polymerase. One patient lost HBs, e antigens (Ags) and gained anti-HBs, e antibodies, while one lost HBs Ag and another HBe Ag. 2'-5' oligoadenylate synthetase activity in mononuclear cells in the peripheral blood did not change during treatment. The number of CD4 positive (helper/inducer) cells and natural killer cell activity increased after therapy (p less than 0.05, p less than 0.01). These results suggest that rIL 2 acts as an immunomodulatory agent enhancing host immune activity and may be beneficial in patients with chronic HB virus infection.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3501387      PMCID： PMC1433944          DOI： 10.1136/gut.28.12.1648

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  8 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

Review 2.  Antiviral therapy in hepatitis B infection.

Authors:  H C Thomas; L J Scully
Journal:  Br Med Bull       Date:  1985-10       Impact factor: 4.291

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2.

Authors:  P Ralph; G Jeong; K Welte; R Mertelsmann; H Rabin; L E Henderson; L M Souza; T C Boone; R J Robb
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

5.  DNA polymerase associated with human hepatitis B antigen.

Authors:  P M Kaplan; R L Greenman; J L Gerin; R H Purcell; W S Robinson
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

6.  Relationship of HLA protein display to activation of 2-5A synthetase in HBe antigen or anti-HBe positive chronic HBV infection.

Authors:  T Ikeda; M Pignatelli; A M Lever; H C Thomas
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

7.  Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2.

Authors:  J Vilcek; D Henriksen-Destefano; D Siegel; A Klion; R J Robb; J Le
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  A sensitive micromethod for generating and assaying allogeneically induced cytotoxic human lymphocytes.

Authors:  J M Zarling; M McKeough; F H Bach
Journal:  Transplantation       Date:  1976-06       Impact factor: 4.939
  8 in total
  5 in total

Review 1.  Hepatitis B virus. New and evolving issues.

Authors:  B Yoffe; C A Noonan
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

2.  Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

Authors:  S Yamaguchi; M Onji; H Kondoh; H Miyaoka; Y Ohta
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

Review 3.  Historical treatment of chronic hepatitis B and chronic hepatitis C.

Authors:  P Ferenci
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 4.  Migraine.

Authors:  Michel D Ferrari; Peter J Goadsby; Rami Burstein; Tobias Kurth; Cenk Ayata; Andrew Charles; Messoud Ashina; Arn M J M van den Maagdenberg; David W Dodick
Journal:  Nat Rev Dis Primers       Date:  2022-01-13       Impact factor: 52.329

Review 5.  Cytokines and Chemokines in HBV Infection.

Authors:  Shihong Zhong; Tianling Zhang; Libo Tang; Yongyin Li
Journal:  Front Mol Biosci       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.